Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer

BJU International

Volumn 107, Issue 10, 2011, Pages 1605-1610

  Maarouf, Aref M ^a   Khalil, Salem ^a   Salem, Emad A ^a,b   Eladl, Mahmoud ^a   Nawar, Nashwa ^a   Zaiton, Fatma ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b NONE   (Egypt)

Author keywords

bladder preservation; multimodality therapy; muscle invasive bladder cancer

Indexed keywords

CISPLATIN; COBALT 60; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CANCER; BLADDER MUSCLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; DIARRHEA; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; THORAX RADIOGRAPHY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT PLANNING; TUMOR BIOPSY;

EID: 79955402194     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09564.x     Document Type: Article

References (39)

1. Jakse G, Algaba F, Fossa S, Stenzl A, Sternberg C,. Guidelines on bladder cancer, Muscle-invasive and metastatic. European Association of Urology, Guidelines. 2007: pp. 1-24
2. Madersbacher S,. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21 (4): 690-6 (Pubitemid 46621904)
3. Stein JP,. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. J Urol 2009; 181 (5): 2052-9
4. Barbieri CE, Lee B, Cookson MS, et al,. Association of procedure volume with radical cystectomy in a nationwide database. J Urol 2007; 178: 1418-21
5. Kessler TM, Burkhard FC, Studer UE,. Clinical indications and outcomes with nerve-sparing cystectomy in patients with bladder cancer. Urol Clin North Am 2005; 32: 165-75 (Pubitemid 40603291)
6. Bhatta Dhar N, Kessler TM, Mills RD, Burkhard F, Studer UE,. Nerve-sparing radical cystectomy and orthotopic bladder replacement in female patients. Eur Urol 2007; 52: 1006-14 (Pubitemid 47332031)
7. Cervek J, Cufer T, Zakotnik B, et al,. Invasive bladder cancer: our experience with bladder sparing approach. Int J Radiat Oncol Biol Phys 1998; 41: 273-8 (Pubitemid 28243537)
8. Herr HW,. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19: 89-93 (Pubitemid 32063483)
9. Leibovici D, Kassouf W, Pisters LL, et al,. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology 2007; 70: 473-6 (Pubitemid 47464510)
10. Solsona E, Iborra I, Ricõs JV, et al,. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term follow-up of a prospective study. J Urol 1998; 159: 95-8 (Pubitemid 127739880)
11. Roosen JU, Geertsen U, Jahn H, et al,. Invasive, high grade transitional cell carcinoma of the bladder treated with transurethral resection. A survival analysis focusing on TUR as monotherapy. Scand J Urol Nephrol 1997; 31: 39-42 (Pubitemid 27105239)
12. Shipley WU, Kaufman DS, Zietman AL, Griffin PP, Heney NM, Althausen AF,. Selective bladder preservation by combined modality therapy for invasive bladder cancer. Eur J Cancer 1995; 31A (Suppl. 5): S239
13. Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zietman AL,. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer. Eur Urol 1998; 33 (Suppl. 4): 32-4 (Pubitemid 28230285)
14. Housset M, Dufour E, Maulard-Durtux C,. Concomitant 5-fluouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer. Proc Am Soc Clin Oncol 1997; 16: 1139A (abstr)
15. Weiss C, Wolze C, Engehausen DG, et al,. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 2006; 24 (15): 2318-24 (Pubitemid 46630663)
16. Rodel C, Grabenbauer GG, Kuhn R, et al,. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20: 3061-71 (Pubitemid 34791095)
17. Danesi DT, Arcangeli G, Crucian E, et al,. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy long-term results. Cancer 2004; 101: 2540-8 (Pubitemid 39532283)
18. Stenzl A, Cowan NC, Santis MD, et al,. Guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol Guidlines 2008; 42: 37-8
19. Bayraktar Z, Gurbuz G, Tasci AI, et al,. Staging error in the bladder tumor: the correlation between stage of TUR and cystectomy. Int Urol Nephrol 2001; 33: 627-9 (Pubitemid 35282648)
20. Raghavan D, Shipley WU, Garnick MB, et al,. Biology and management of bladder cancer. N Engl J Med 1990; 322: 1129-38 (Pubitemid 20149531)
21. Sherwood BT, Jones GDD, Mellon JK, Kockelbergh RC, Steward WP, Symonds RP,. Concomitant chemoradiotherapy for muscle-invasive bladder cancer: the way forward for bladder preservation? Clin Oncol 2005; 17 (3): 160-6 (Pubitemid 40468481)
22. Schoenberg MP, Gonzalgo ML,. Management of invasive and metastatic bladder cancer. In, Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology, Philadelphia, Elsevier Saunders, 2007
23. Shipley WU, Kaufman DS, Zehr E, et al,. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladdercancer. Urology 2002; 60: 62-7, discussion 67-8 (Pubitemid 34722947)
24. Zietman AL, Grocela J, Zehr E, et al,. Selective bladder conservation using transurethral resection, chemotherapy, and radiation:management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001; 58 (3): 380-5 (Pubitemid 32816355)
25. Kaufman DS, Shipley W, Greffen PP, et al,. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993; 329: 1377-82 (Pubitemid 23317347)
26. Chauvet B, Brewer Y, Felix-Faure C, et al,. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy. J Urol 1996; 156: 1258-62 (Pubitemid 26307589)
27. Fellin G, Graffer U, Bolner A, et al,. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single institution phase II study. Br J Urol 1997; 80: 44-9
28. Housset M, Maulard C, Chretien Y, et al,. Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993; 11: 2150-7 (Pubitemid 23332251)
29. Vikram B, Chadha M, Malamud SC, et al,. Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle invasive carcinoma of the urinary bladder. Cancer 1998; 82: 918-22 (Pubitemid 28104172)
30. Kachnic LA, Kaufman DS, Heney NM, et al,. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997; 15: 1022-9 (Pubitemid 27106286)
31. Dunst J, Sauer R, Schrott KM, et al,. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 1994; 30: 261-6 (Pubitemid 24309726)
32. Sternberg CN, Calabro F, Marini L, et al,. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol 1999; 10: 1301-5
33. Herr HW, Scher HI,. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16: 1298-301 (Pubitemid 28175743)
34. Ott OJ, Rödely C, Weissy C, et al,. Radiochemotherapy for bladder cancer. Clin Oncol 2009; 21: 557-65
35. Leibovici D, Kassouf W, Pisters L, et al,. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology 2007; 70: 473-6 (Pubitemid 47464510)
36. Sanchez-Ortiz R, Huang WC, Mick R, et al,. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003; 169: 110-5 (Pubitemid 35461564)
37. Perdona S, Autorino R, Damiano R, et al,. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 2008; 112: 75-83
38. Weiss C, Engehausen DG, Krause FS, et al,. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1072-80 (Pubitemid 47048579)
39. Zeitman AL, Shipley WU, Kaufman DS, et al,. A Phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998; 160: 1673-7 (Pubitemid 128746736)